ACL
AUSTRALIAN CLINICAL LABS LIMITED
$2.83
▲ +1.62%
Market cap
$527M
Turnover
$912,921
Last price
$2.83
Day change
+1.62%
Announcements
3
Range, past year
Open 2.400 · Low 1.832 · Now 2.825 · High 3.240
Open ACL in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
ACL momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-29.
Momentum quality
65/100
Wyckoff phase
Uptrend3d
Trend stage
Neutral
1 Day
+1.6%
1 Week
-0.9%
1 Month
+1.6%
1 Year
+15.8%
RSI
56
Avg daily range
3.1%
AUSTRALIAN CLINICAL LABS LIMITED scores 65 out of 100 for momentum quality, a reading rated medium confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Uptrend, where it has been for 3 trading days. The weekly timeframe reads Uptrend, which agrees with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads moderate.
What stands out
- Solid momentum quality (MQS 65)
- Above SMA50 for 91 days
- RSI in healthy zone (56)
Points to watch
Nothing flagged for ACL on this reading.
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsACL announcements
Recent price-sensitive releases.
- 2026-08-17 Appendix 4E and FY26 financial reports Sustainability/Climate Action Report | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report | Dividend Record Date | Dividend Pay Date | Dividend Rate
- 2026-08-17 FY26 financial results investor presentation Company Presentation | Web Cast | Preliminary Final Report | Dividend Rate
- 2026-05-28 Appointment of new Group CEO
More Health Care stocks
Most traded in the same sector.